Anti-Properdin MoAb as a Novel Therapeutic for Arthritis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$103,103.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43AR048476-01A1
Award Id:
66083
Agency Tracking Number:
AR048476
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
NOVELMED THERAPEUTICS, INC., BIOENTERPRISE, 11000 CEDAR RD, CLEVELAND, OH, 44106
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
REKHABANSAL
(440) 477-9874
REKHA@NOVELMED.COM
Business Contact:
(440) 411-9874
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): The complement system is an important host defense system, however, inappropriate and/or excessive activation of the complement system has been implicated as contributing to the pathogenesis of many disease states, including rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is characterized by the occurrence of painful, swollen joints and none of the drugs currently administered to RA patients has been shown to cause regression of the disease. Therefore, there is a clinical need for potent new therapeutic agents for RA. There is evidence that the complement alternative pathway (AP) contributes significantly to the generation of pro-inflammatory agents in RA. Complement activation products such as C3a, C5a, and sMAC have been found within inflamed rheumatic joints and a positive correlation has been reported between the degree of complement activation and the severity of RA. Gliatech Inc. has identified a potent inhibitor of the AP, which consists of a blocking monoclonal antibody (GT6067) to properdin. Based on its ability to prevent AP activation in models of immune complex-mediated inflammation, there is reason to believe that such a MoAb holds great promise as an effective therapeutic agent for the treatment of RA. The focus of this study is to evaluate GT6067 in an antigen-induced model of arthritis in rabbits. This rabbit model possesses several key similarities with human rheumatoid arthritis and has been widely used in studies to identify novel RA therapeutic agents. Both Rekha Bansal, Ph.D. (P.I.) and James B. Parent are co-authors of the issued patent" Gupta-BansalR., Brunden, K. R. and Parent, J. B., A process of inhibiting complement activation via the alternative pathway. U.S. Patent 6,333,034B1, December, 2002 Key Words Complement; Monoclonal Antibodies; Properdin; Inflammation; Reverse Passive Arthus; Arthritis

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government